June 26, 2015 139 th Ordinary general meeting of shareholders Christophe Weber President & Chief Executive Officer 139 th Ordinary General Meeting of Shareholders | June 26, 2015 1 Important notice Forward-Looking Statements This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward looking statements can sometimes be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target, " "forecast," or "intend" or other similar words or expressions of the negative thereof. Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward looking statements contained in this presentation. These risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding the Company's business, including general economic conditions in the US and worldwide; (2) competitive pressures; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) decisions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates; and (8) integration activities with acquired companies. We assume no obligation to update or revise any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise. Medical Information This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drug including the ones under development. Underlying Revenue & Underlying Core Earnings - Underlying performance aims at understanding the real performance of the business. - Core Earnings is calculated from operating profit by excluding the impact of exceptional items, such as purchase accounting, amortization and impairment loss of intangible assets, restructuring costs and litigation costs - Underlying Revenue and Underlying Core Earnings excludes the same items plus product divestments and foreign exchange Please note these terms are non-GAAP items, used for internal evaluation purposes and are not audited
14
Embed
139th Ordinary general meeting of shareholders · 139th Ordinary General Meeting of Shareholders | June 26, 2015 290.3 281.3 571.2 548.1 297.9 341.0 237.8 250.6 278.4 300.9 FY 2013
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
June 26, 2015
139th Ordinary general meeting of shareholders
Christophe Weber
President & Chief Executive Officer
139th Ordinary General Meeting of Shareholders | June 26, 20151
Important notice
Forward-Looking StatementsThis presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future.All forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward looking statements can sometimes be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target, " "forecast," or "intend" or other similar words or expressions of the negative thereof. Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward looking statements contained in this presentation. These risks and uncertainties include, but are not limited to, (1) the economic circumstancessurrounding the Company's business, including general economic conditions in the US and worldwide; (2) competitive pressures;(3) applicable laws and regulations; (4) the success or failure of product development programs; (5) decisions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy ofmarketed products or product candidates; and (8) integration activities with acquired companies.We assume no obligation to update or revise any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise.
Medical InformationThis presentation contains information about products that may not be available in all countries, or may be available under differenttrademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drug including the ones under development.
Underlying Revenue & Underlying Core Earnings- Underlying performance aims at understanding the real performance of the business.- Core Earnings is calculated from operating profit by excluding the impact of exceptional items, such as purchase accounting,
amortization and impairment loss of intangible assets, restructuring costs and litigation costs- Underlying Revenue and Underlying Core Earnings excludes the same items plus product divestments and foreign exchange
Please note these terms are non-GAAP items, used for internal evaluation purposes and are not audited
139th Ordinary General Meeting of Shareholders | June 26, 2015
1781 ~Founding –
Modernization
1944 ~Business
diversification
1993 ~Pharmaceutical focus Overseas expansion
2003 ~Globalization
Transforming into Global One Takeda
2
234 years of Takeda’s history
139th Ordinary General Meeting of Shareholders | June 26, 20153
The pharmaceutical market evolutionGrowth driven by US & Emerging Markets (EM)
* New products: Products launched in or after 2009 excluding new formulation or fixed dose combination of existing drugs: DEXILANT, ULORIC, NESINA, AZILVA, ADCETRIS, BRINTELLIX, ENTYVIO, CONTRAVE, TAKECAB etc.
0
10
20
30
FY2013 FY2014
Revenue (billion yen) @ Constant currency
0
20
40
FY2013 FY2014Prim
ary
care
pr
oduc
tS
peci
alty
prod
uct
139th Ordinary General Meeting of Shareholders | June 26, 2015
290.3 281.3
571.2 548.1
297.9 341.0
237.8 250.6
278.4 300.9
FY 2013 FY 2014
Growth driven by innovation in the U.S. and Europe, and by value brands1 in Emerging Markets
+ 14.5%
- 4.1%
+ 5.4%
+ 8.1%
- 3.1%
Growth rate
+ 2.8%1: Brand generics and OTC2: Others: Representing licensees business and Consumer Healthcare business, etc.
Emerging markets
Europe and Canada
U.S.
Japan
Others2
10
(billion yen)
Underlying growth 1,675.7 1,721.9
139th Ordinary General Meeting of Shareholders | June 26, 2015
20142013 NycomedMillenniumTakedaorigin
Underlying basebillion yen @ constant foreign exchange rate
2014 growth driven by Millennium, Nycomed and other acquired / licensed products
* Including Brintellix, Adcetris, Lotriga, etc.
Nycomed created Takeda's presence in EM
+2.8%
11
-4.3%
-39 +33
+13
+40
Other acquired/licensed
products*
Underlying revenue growth
1,675.7
1,721.9
139th Ordinary General Meeting of Shareholders | June 26, 2015
Takeda is strongly committed to CSR activities to support patients and society
12
In 2014, Takeda conducted over 40 impactful CSR projects covering healthcare education and capacity building of NGOs
Healthcare Access Program in Asia(2009-2014)- Hygiene- Nutrition- Medical services- HIV/AIDs training
The Great East Japan EarthquakeReconstruction Support
(2011-2020)
Contribution to the Global Fund programs to treat
HIV/AIDs, TB, and Malaria in Africa (2009-2019) Volunteer activities
over the world(e.g., fundraising and
health education)
139th Ordinary General Meeting of Shareholders | June 26, 2015
FY2015 Strategy and Guidance
13
139th Ordinary General Meeting of Shareholders | June 26, 2015
Pharmaceutical market growth driven mainly by EM and US